AGILE THERAPEUTICS INC
DelistedCIK 1261249fmd_0CEGA2K160ZFTAQRQ5QAP214QWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2024, 47 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 11 | 20 |
| Cost of revenue | – | – | – | – | – | – | 0 | 11 | 7 | 9 |
| Gross profit | – | – | – | – | – | – | 0 | (7) | 4 | 11 |
| Research and development | 13 | 26 | 21 | 14 | 10 | 10 | 14 | 6 | 3 | 2 |
| Selling, general and administrative | – | – | – | – | 9 | 9 | 36 | 58 | 42 | 28 |
| Total operating expenses | 19 | 33 | 30 | 27 | 20 | 19 | 50 | 64 | 57 | 30 |
| Operating income | (19) | (33) | (30) | (27) | (20) | (19) | (49) | (71) | (53) | (20) |
| Interest expense | 2 | 2 | 2 | 2 | 1 | – | 3 | 4 | 3 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | (3) | (2) | (1) | (1) | 0 | (3) | (0) | 22 | 5 |
| Income before taxes | (20) | (36) | (32) | (28) | (20) | (19) | (52) | (71) | (30) | (14) |
| Income tax expense | (4) | (6) | (3) | – | (0) | – | – | – | (5) | – |
| Net income from continuing operations | (16) | (30) | (29) | – | (20) | – | – | – | (25) | – |
| Net income | (16) | (30) | (29) | (28) | (20) | (19) | (52) | (71) | (25) | (14) |
| Net income to common shareholders | (16) | (30) | (29) | – | – | – | – | – | – | – |